Adverse events to antiretrovirals in the Swiss HIV Cohort Study : effect on mortality and treatment modification

• Published in: Antiviral therapy 2007-01, Vol.12 (8), p.1157-1164
• Main Authors: KEISER, Olivia, FELLAY, Jacques, OPRAVIL, Milos, HIRSCH, Hans H, HIRSCHEL, Bernard, BERNASCONI, Enos, VERNAZZA, Pietro L, RICKENBACH, Martin, TELENTI, Amalio, FURRER, Hansjakob
• Format: Article
• Language: English
• Subjects: Adult; Anti-Retroviral Agents - adverse effects; Anti-Retroviral Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral Therapy, Highly Active; Antiviral agents; Biological and medical sciences; Cohort Studies; Cross-Sectional Studies; Female; HIV; HIV Infections - drug therapy; HIV Infections - mortality; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Survival Analysis; Switzerland; Treatment Outcome; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Withholding Treatment
• ISSN: 1359-6535; 2040-2058
• DOI: 10.1177/135965350701200808

Antiretroviral therapy (ART) decreases morbidity and mortality in HIV-infected patients but is associated with considerable adverse events (AEs). We examined the effect of AEs to ART on mortality, treatment modifications and drop-out in the Swiss HIV Cohort Study. A cross-sectional evaluation of prevalence of 13 clinical and 11 laboratory parameters was performed in 1999 in 1,078 patients on ART. AEs were defined as abnormalities probably or certainly related to ART. A score including the number and severity of AEs was defined. The subsequent progression to death, drop-out and treatment modification due to intolerance were evaluated according to the baseline AE score and characteristics of individual AEs. Of the 1,078 patients, laboratory AEs were reported in 23% and clinical AEs in 45%. During a median follow up of 5.9 years, laboratory AEs were associated with higher mortality with an adjusted hazard ratio (HR) of 1.3 (95% confidence interval [CI] 1.2-1.5; P < 0.001) per score point. For clinical AEs no significant association with increased mortality was found. In contrast, an increasing score for clinical AEs (HR 1.11,95% CI 1.04-1.18; P = 0.002), but not for laboratory AEs (HR 1.07, 95% CI 0.97-1.17; P = 0.17), was associated with antiretroviral treatment modification. AEs were not associated with a higher drop-out rate. The burden of laboratory AEs to antiretroviral drugs is associated with a higher mortality. Physicians seem to change treatments to relieve clinical symptoms, while accepting laboratory AEs. Minimizing laboratory drug toxicity seems warranted and its influence on survival should be further evaluated.